Foreword; Preface; Contents; Contributors; Cardiovascular Disease Spectrum in Chronic Kidney Disease; 1 Endothelial Dysfunction and Nitric Oxide: Albuminuria as a Central Marker; Endothelial Function; Endothelial Activation and Endothelial Dysfunction; Evaluation of Endothelial Dysfunction; Nitric Oxide and Endothelium; Albuminuria and Endothelium; Albuminuria and Cardiovascular Disease; Summary; References; 2 Vascular and Valvular Calcification in Chronic Kidney Disease: Pathogenesis and Clinical Outcomes; Introduction; Vascular Calcification; Valvular Calcification

Pathogenesis of Vascular CalcificationPathogenesis of Valvular Calcification; Pathogenesis of Vascular and Valvular Calcification in CKD and ESKD; Disturbance in Mineral Metabolism; Alteration in Inhibitory Regulation; Increase in Matrix Metalloproteinases (MMP); Chronic Inflammation; Mechanical Stress; Clinical Impact of Vascular Calcification; Medical Strategies to Prevent Calcification; Clinical Impact of Valvular Calcification; Aortic Valve; Mitral Valve; Conclusion; Disclosures; References; 3 Sudden Cardiac Death in CKD and ESKD: Risk Factors, Mechanisms, and Therapeutic Strategies

4 Coronary Artery Disease in CKD: Traditional and Nontraditional Risk Factors, Diagnosis and ManagementEpidemiology of CAD in CKD Patients; Pathophysiology; Traditional and Nontraditional Risk Factors; Clinical Presentation; Reduction of CAD Risk in CKD Patients; Medical Therapy; Statins; Blood Pressure Management; Antiplatelet Therapy; Revascularization in CKD Patients; Stable Angina; STEMI and NSTEMI; CABG Versus PCI in CKD Patients; References; 5 CKD Associated Cardiomyopathy: Molecular Mechanisms, Imaging Modalities, Disease Evolution and Interventions; Introduction; Molecular Mechanisms

Renin-Angiotensin-Aldosterone System (RAAS)Abnormal Calcium and Phosphate Metabolism; Phosphate; Fibroblast Growth Factor 23 (FGF-23); Parathyroid Hormone; Vitamin D; Hyperuricemia; Protein Bound Uremic Toxins; Cardiotonic Steroids; Insulin Resistance; Imaging Modalities in CKD-Associated Cardiomyopathy; Left Ventricular Mass; Myocardial Fibrosis; Late Enhancement Imaging; T1 Mapping; Gadolinium-Based Contrast Agents in CKD; Computed Tomography; Cardiac Magnetic Resonance as the Proposed Imaging Modality of Choice in CKD; Evolution of CKD-Associated Cardiomyopathy; Interventions for CKD-Associated Cardiomyopathy.